What's in Gilead Sciences, Inc.'s pipeline?

Gilead Sciences, Inc. has 24 drugs in our index: 19 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 4 in Phase 1.

Which companies overlap with Gilead Sciences, Inc.'s portfolio?

Top competitors by shared drug class: , AbbVie, Abbvie Deutschland Gmbh Co. Kg, AstraZeneca, Centre Hospitalier Universitaire de Saint Etienne.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gilead.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Gilead Sciences, Inc. — Portfolio Competitive Intelligence Brief

Gilead Sciences, Inc. (GILD) pipeline: 19 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

GILD (NASDAQ) 19 marketed 0 filed 0 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Livdelzi	SELADELPAR	marketed			Metabolic	2026-01-01
Sunlenca	LENACAPAVIR	marketed			Infectious Disease	2022-01-01
Veklury	remdesivir	marketed	Nucleotide analog RNA polymerase inhibitor	SARS-CoV-2 RNA polymerase	Metabolic	2020-01-01
Jyseleca	FILGOTINIB	marketed		Tyrosine-protein kinase JAK1	Immunology	2020-01-01
Biktarvy	BICTEGRAVIR	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		Immunology	2018-01-01
Vemlidy	TENOFOVIR ALAFENAMIDE	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		Immunology	2015-01-01
Tybost	COBICISTAT	marketed	Cytochrome P450 3A Inhibitor [EPC]	Cytochrome P450 3A	Oncology	2012-01-01
Vitekta	ELVITEGRAVIR	marketed	Cytochrome P450 3A Inhibitor [EPC]		Immunology	2012-01-01
Letairis	AMBRISENTAN	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	Cardiovascular	2007-01-01
Emtriva	EMTRICITABINE	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		Immunology	2003-01-01
Hepsera	ADEFOVIR DIPIVOXIL	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	Infectious Disease	2002-01-01
Vistide	CIDOFOVIR	marketed	cidofovir		Immunology	1996-01-01

Therapeutic area mix

Immunology · 6
Infectious Disease · 5
Metabolic · 2
Cardiovascular · 1
Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2032-08-15 — Biktarvy · 9296769 · US
2032-08-15 — Biktarvy · 8754065 · US
2033-02-15 — Biktarvy · 8754065*PED · US
2033-02-15 — Biktarvy · 9296769*PED · US
2033-12-19 — Biktarvy · 9732092 · US
2033-12-19 — Biktarvy · 9216996 · US
2035-06-19 — Biktarvy · 9708342 · US
2035-06-19 — Biktarvy · 10385067 · US
2036-11-08 — Biktarvy · 10548846 · US

Competitive overlap (companies sharing drug classes)

· 3 shared drug classes
AbbVie · 1 shared drug class
Abbvie Deutschland Gmbh Co. Kg · 1 shared drug class
AstraZeneca · 1 shared drug class
Centre Hospitalier Universitaire de Saint Etienne · 1 shared drug class
Idorsia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gilead Sciences, Inc.:

Cite this brief

Drug Landscape (2026). Gilead Sciences, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gilead. Accessed 2026-05-15.